Skip to main content

Typhoid

4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
6100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
Typhoid Vi vaccinePhase 4Vaccine
Typhoid Vi vaccinePhase 4Vaccine
Typhoid Vi vaccinePhase 4Vaccine
Emergent BioSolutions
1 program
1
Dose of 5.0 x 10^9 CFUPhase 21 trial
Active Trials
NCT00679172Completed187Est. Dec 2008
GSK
GSKLONDON, United Kingdom
3 programs
Typhoid Vi vaccinePHASE_4Vaccine1 trial
Typhoid Vi vaccinePHASE_4Vaccine1 trial
Typhoid Vi vaccinePHASE_4Vaccine1 trial
Active Trials
NCT00125008Completed37,673Est. Jan 2008
NCT00125047Completed27,231Est. Aug 2007
NCT00131820Completed100,742Est. Jan 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKTyphoid Vi vaccine
GSKTyphoid Vi vaccine
GSKTyphoid Vi vaccine
Emergent BioSolutionsDose of 5.0 x 10^9 CFU

Clinical Trials (4)

Total enrollment: 165,833 patients across 4 trials

NCT00125008GSKTyphoid Vi vaccine

Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

Start: May 2003Est. completion: Jan 200837,673 patients
Phase 4Completed
NCT00131820GSKTyphoid Vi vaccine

Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam

Start: Dec 2001Est. completion: Jan 2007100,742 patients
Phase 4Completed
NCT00125047GSKTyphoid Vi vaccine

Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood

Start: Oct 2001Est. completion: Aug 200727,231 patients
Phase 4Completed
NCT00679172Emergent BioSolutionsDose of 5.0 x 10^9 CFU

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Start: May 2008Est. completion: Dec 2008187 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Vaccine is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.